



Zeal & Innovation in **M**edicine

Ref No.: ZLL/CS/BM/BSE-NSE

Date : 09.11.2024

BSE Limited, Compliance Department, P. J. Towers, Dalal Street, Mumbai – 400 001 (Scrip Code - 541400)	National Stock Exchange of India Limited, Listing Compliance Department, Exchange Plaza, Bandra-Kurla Complex, Bandra (E), Mumbai – 400 051 (Symbol - ZIMLAB)
--------------------------------------------------------------------------------------------------------------------	---------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Dear Sir,

Sub : **Outcome of Board Meeting held on 09.11.2024**

Ref : **Notice of Board Meeting dt. 04.11.2024**

In terms of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the Board of Directors in their meeting held today have inter-alia considered and approved :

1. Unaudited Financial Results (Consolidated and Standalone) of the Company for the quarter and half year ended 30th September, 2024.

Copy of the Unaudited Financial Results (Consolidated and Standalone) along with the Limited Review Report issued by Walker Chandiook & Co LLP, Statutory Auditors of the Company is enclosed herewith.

2. Changes in the Senior Management of the Company :

- a. Categorization of Dr. Chandrashekhar Mainde, Technical Director as the Senior Management Personnel of the Company.
- b. Categorization of Dr. Uttam Kedar, Assistant Vice President – R&D as the Senior Management Personnel of the Company.

The brief details of the aforesaid appointment of Senior Management Personnel as prescribed under SEBI Listing Regulations read with SEBI circular SEBI/HO/CFD/CFDPoD1/ P/CIR/2023/123 dated 13th July, 2023 is attached as Annexure-A.

Kindly take the intimation on record.

The Board Meeting commenced at 03:00 p.m. and concluded at 06:15 p.m.

Thanking you,

Yours faithfully,

For ZIM LABORATORIES LIMITED

(Piyush Nikhade)
Company Secretary and Compliance Officer
Membership No. A38972
Encl : As above

ZIM LABORATORIES LIMITED

www.zimlab.in | info@zimlab.in | CIN : L99999MH1984PLC032172

Walker Chandiook & Co LLP

16th Floor, Tower III,
One International Center,
S B Marg, Prabhadevi (W),
Mumbai - 400013
Maharashtra, India
T +91 22 6626 2699
F +91 22 6626 2601

Independent Auditor's Review Report on Consolidated Unaudited Quarterly Financial Results and Year to Date Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of ZIM Laboratories Limited

1. We have reviewed the accompanying statement of unaudited consolidated financial results ('the Statement') of **ZIM Laboratories Limited** ('the Holding Company') and its subsidiaries (the Holding Company and its subsidiaries together referred to as 'the Group'), (refer Annexure 1 for the list of subsidiaries included in the Statement) for the quarter ended **30 September 2024** and the consolidated year to date results for the period 01 April 2024 to 30 September 2024, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations').
2. This Statement, which is the responsibility of the Holding Company's management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the SEBI Circular CIR/CFD/CMD1/44/2019 dated 29 March 2019 issued by the SEBI under Regulation 33 (8) of the Listing Regulation, to the extent applicable.

ZIM Laboratories Limited

Independent Auditor's Review Report on Consolidated Unaudited Quarterly Financial Results and Year to Date Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

4. Based on our review conducted and procedures performed as stated in paragraph 3 above nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **Walker Chandiook & Co LLP**

Chartered Accountants

Firm Registration No:001076N/N500013

KHUSHROO
B PANTHAKY

Digitally signed by
KHUSHROO B
PANTHAKY
Date: 2024.11.09
16:30:49 +05'30'

Khushroo B. Panthaky

Partner

Membership No:042423

UDIN:24042423BKCMXL8847

Place: Mumbai

Date: 09 November 2024

ZIM Laboratories Limited
Independent Auditor's Review Report on Consolidated Unaudited Quarterly Financial Results and
Year to Date Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations
and Disclosure Requirements) Regulations, 2015 (as amended)

Annexure 1

List of entities included in the Statement

Subsidiary companies

1. ZIM Laboratories FZE
2. ZIM Health Technologies Limited
3. SIA ZIM Laboratories Limited
4. ZIM Thinorals Private Limited
5. ZIM Laboratories Middle East DMCC (w.e.f. 28 September 2023)
6. ZIMTAS PTY Limited, Australia (w.e.f. 5 March 2024)

KHUSHROO
B PANTHAKY

Digitally signed by
KHUSHROO B
PANTHAKY
Date: 2024.11.09
16:31:18 +05'30'



ZIM Laboratories Limited

Registered Office : Sadoday Gyan(Ground Floor),Opp.NADT,Nelson Square Nagpur - 440013, Maharashtra, India
CIN:L99999MH1984PLC032172, Website: www.zimlab.in

A. STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER & HALF YEAR ENDED 30 SEPTEMBER 2024

(Rs. in lakhs, unless otherwise stated)

Sr. No.	Particulars	Quarter ended			Half Year ended		Year ended
		30.09.2024	30.06.2024	30.09.2023	30.09.2024	30.09.2023	31.03.2024
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Income						
	a) Revenue from operations	9,214.33	8,182.44	8,582.61	17,396.77	15,326.90	36,742.44
	b) Other income	132.08	99.89	142.15	231.97	253.69	518.39
	Total income	9,346.41	8,282.33	8,724.76	17,628.74	15,580.59	37,260.83
2	Expenses						
	a) Cost of materials consumed	3,551.84	3,100.93	4,096.35	6,652.77	7,270.36	17,769.83
	b) Purchases of stock-in-trade	313.84	265.74	204.04	579.58	267.13	779.61
	c) Changes in inventories of finished goods, stock-in-trade and work-in-progress	345.17	256.40	(308.40)	601.57	(434.05)	(1,405.32)
	d) Employee benefits	1,545.13	1,450.92	1,282.68	2,996.05	2,545.96	5,334.27
	e) Finance costs	288.75	285.85	121.69	574.60	295.11	692.44
	f) Depreciation and amortisation	500.09	494.28	408.55	994.37	811.11	1,595.18
	g) Other expenses	2,505.30	2,304.77	2,375.51	4,810.07	4,262.09	10,130.58
	Total expenses	9,050.12	8,158.89	8,180.42	17,209.01	15,017.71	34,896.59
3	Profit before tax (1-2)	296.29	123.44	544.34	419.73	562.88	2,364.24
4	Tax expense						
	Current Tax	24.70	27.62	84.06	52.32	87.90	94.15
	Deferred Tax	33.45	5.99	45.33	39.44	37.37	545.46
	Total tax expense	58.15	33.61	129.39	91.76	125.27	639.61
5	Net Profit after tax (3-4)	238.14	89.83	414.95	327.97	437.61	1,724.63
6	Other comprehensive income - profit/(loss)						
	a) Items that will not be reclassified to profit or loss	(13.47)	(13.47)	(16.29)	(26.94)	(32.57)	(53.88)
	b) Tax (expense)/credit on the items that will not be reclassified to profit or loss	3.92	3.92	4.74	7.84	9.48	15.69
	c) Items that may be reclassified to profit or loss	24.84	2.50	12.32	27.34	9.46	13.29
	d) Tax (expense)/credit on the items that will be reclassified to profit or loss	-	-	-	-	-	-
	Other comprehensive income (net of tax) - profit/(loss)	15.29	(7.05)	0.77	8.24	(13.63)	(24.90)
7	Total comprehensive income (5+6)	253.43	82.78	415.72	336.21	423.98	1,699.73
8	Net Profit after tax attributable to						
	Owners	238.14	89.83	414.95	327.97	437.61	1,724.64
	Non-controlling interest	-	(0.00)	-	(0.00)	-	(0.01)
9	Other comprehensive Income attributable to						
	Owners	15.29	(7.05)	0.77	8.24	(13.63)	(24.90)
	Non-controlling interest	-	(0.00)	-	(0.00)	-	-
10	Total Comprehensive Income attributable to						
	Owners	253.43	82.78	415.72	336.21	423.98	1,699.74
	Non-controlling interest	-	(0.00)	-	(0.00)	-	(0.01)
11	Paid-up equity share capital (face value of Rs. 10/- each)	4,872.58	4,872.58	4,872.58	4,872.58	4,872.58	4,872.58
12	Other equity (revaluation reserve : Rs. Nil)						19,002.00
13	Earnings per share (face value of Rs. 10/- each) (not annualised for the quarters) (Rs.)						
	Basic	0.49	0.18	0.85	0.67	0.90	3.54
	Diluted	0.49	0.18	0.85	0.67	0.90	3.54



B. Consolidated Balance Sheet

	As at 30.09.2024 Rs. in lakhs (Unaudited)	As at 31.03.2024 Rs. in lakhs (Audited)
ASSETS		
Non-current assets		
Property, Plant and Equipment	16,440.49	15,693.35
Capital work-in-progress	3,334.70	2,351.60
Goodwill on consolidation	16.94	16.94
Other intangible assets	311.45	372.34
Intangible assets under development	2,498.18	1,876.68
Financial Assets		
Investments	5.15	5.15
Other financial assets	86.06	78.55
Non-current tax assets (net)	376.07	386.78
Other non-current assets	504.69	1,135.99
	23,573.73	21,917.38
Current assets		
Inventories	6,792.58	8,126.29
Financial Assets		
Trade receivables	8,158.81	10,016.54
Cash and cash equivalents	507.50	960.02
Bank balances other than cash and cash equivalents	73.95	86.38
Other financial assets	20.07	31.85
Other current assets	3,609.00	3,543.77
	19,161.91	22,764.85
TOTAL ASSETS	42,735.64	44,682.23
EQUITY AND LIABILITIES		
Equity		
Equity share capital	4,872.58	4,872.58
Other equity	19,403.60	19,002.00
Equity attributable to equity holders of the parent	24,276.18	23,874.58
Non controlling interest	0.06	0.03
Total equity	24,276.24	23,874.61
Liabilities		
Non-current liabilities		
Financial Liabilities		
Borrowings	4,010.18	3,560.06
Other financial liabilities	352.55	294.95
Deferred tax liabilities (net)	1,041.69	1,010.09
	5,404.42	4,865.10
Current liabilities		
Financial Liabilities		
Borrowings	5,725.09	7,075.20
Lease Liabilities	333.79	247.18
Trade payables		
-total outstanding due of micro enterprises and small enterprises	68.49	6.31
-total outstanding due of creditors other than micro enterprises and small enterprises	4,703.77	6,231.78
Other financial liabilities	921.67	1,077.72
Other current liabilities	1,232.28	1,224.65
Provisions	57.26	79.68
Current Tax Liabilities (net)	12.63	-
	13,054.98	15,942.52
TOTAL LIABILITIES	18,459.40	20,807.62
TOTAL EQUITY AND LIABILITIES	42,735.64	44,682.23



C. Consolidated Cash Flow Statement

	Half Year ended 30.09.2024 Rs. in lakhs (Unaudited)	Half Year ended 30.09.2023 Rs. in lakhs (Unaudited)
Cash flow from operating activities		
Profit before tax	419.73	562.88
Depreciation and amortisation expense	994.37	811.11
Government Incentive	(5.12)	(4.05)
Interest on Lease deposits	(3.61)	(1.69)
(Gain) on sale of property, plant and equipment (net)	(3.01)	(45.38)
Unrealized Foreign Exchange (Gain)	(78.40)	(69.13)
Provision for employee benefits	(26.94)	(32.57)
Dividend income on investments	(0.75)	(0.60)
Interest income	(2.11)	(2.82)
Employee compensation cost (ESOP costs)	65.39	-
Finance costs	574.60	295.11
Operating profit before working capital changes	1,934.15	1,512.86
Movement in working capital :		
(Decrease) in trade and other payables	(1,416.28)	(985.80)
(Increase)/decrease in inventories	1,333.71	(1,236.93)
Decrease in trade and other receivables	1,857.58	2,408.76
Net Cash generated from operations	3,709.16	1,698.89
Direct taxes paid (net of refunds)	(28.98)	617.28
Net cash from operating activities (A)	3,680.18	2,316.17
Cash flow from investing activities		
Purchases of property, plant and equipment and intangibles (Refer Note i)	(2,459.70)	(3,237.24)
Sale proceeds of property, plant and equipment and intangibles	3.72	46.49
Deposits placed with bank (having original maturity of more than three months)	(34.50)	(150.00)
Maturity of bank deposits (having original maturity of more than three months)	17.50	32.82
Interest received	0.40	1.48
Dividend received	0.75	0.60
Net cash (used in) investing activities (B)	(2,471.83)	(3,305.85)
Cash flow from financing activities		
Deemed equity contribution from shareholder (net)	-	2,140.24
Proceeds from long term borrowings	1,403.86	2,113.55
(Repayment) of long term borrowings	(690.04)	(650.66)
(Repayment) of short term borrowings (net)	(1,545.32)	(1,334.94)
(Repayment) of principal portion of lease obligations	(189.94)	(83.25)
Finance costs paid	(644.25)	(369.64)
Changes in unclaimed dividend bank balances	0.04	0.15
Dividends paid on equity shares (including unclaimed)	(0.04)	(0.15)
Net cash generated from financing activities (C)	(1,665.69)	1,815.30
Effects of exchange rate changes on cash and cash equivalents (D)	4.82	9.46
Net increase in cash and cash equivalents (A+B+C+D)	(452.52)	835.08
Opening cash and cash equivalents	960.02	642.05
Closing cash and cash equivalents	507.50	1,477.13
Components of cash and cash equivalents		
Cash on hand	16.26	20.32
Balances with banks in:		
- Current accounts	491.24	1,456.81
Total Cash and cash equivalents	507.50	1,477.13

Note (i) Includes capital work-in-progress, capital advance, payables for property, plant and equipment, intangibles assets and intangible assets under development.

Note (ii) The Statement of Cashflow has been prepared under the indirect method as set out in Indian Accounting Standard (Ind AS 7) Statement of Cash flows



Notes :

- 1) The above results were reviewed and recommended by the Audit Committee and approved by the Board of Directors at their respective meetings held on 09 November 2024. There are no qualifications in the limited review report issued for the quarter & half year ended 30 September 2024.

- 2) These financial results have been prepared in accordance with the recognition and measurement principles of applicable Indian Accounting Standard ('Ind AS') notified under the Companies (Indian Accounting Standards) Rules, 2015 (as amended), as prescribed under Section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations and guidelines issued by the Securities and Exchange Board of India (SEBI).

- 3) The Company and its subsidiaries are principally engaged in a single business segment which is "pharmaceuticals".

Place: Nagpur
Date: 09 November 2024



**ANWAR
SIRAJ DAUD**

Digitally signed by ANWAR SIRAJ DAUD
DN: cn=ANWAR SIRAJ DAUD, o=ANWAR SIRAJ DAUD,
ou=ANWAR SIRAJ DAUD, postalCode=440002, st=MAHARASHTRA,
street=NAGPUR, c=INDIA, email=ANWAR.SIRAJ.DAUD@ANWAR.SIRAJ.DAUD.COM,
serialNumber=433422b11b06d1f85c8f8e73d1bc5d5da31
5d6c01087132ac29e0d95c
profileName=991820212911594366,
2.5.4.20=91c258f03d2eb12217d9e4d11e7d67d99b05
73b76c622b6c29f8a02, email=ANWAR.DAUD@MILAB.N,
cn=ANWAR SIRAJ DAUD
Date: 2024.11.09 16:19:52 +05'30'

Anwar S. Daud
Managing Director

Walker Chandiook & Co LLP

16th Floor, Tower III,
One International Center,
S B Marg, Prabhadevi (W),
Mumbai - 400013
Maharashtra, India
T +91 22 6626 2699
F +91 22 6626 2601

Independent Auditor's Review Report on Standalone Unaudited Quarterly Financial Results and Year to Date Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of ZIM Laboratories Limited

1. We have reviewed the accompanying statement of standalone unaudited financial results ('the Statement') of **ZIM Laboratories Limited** ('the Company') for the quarter ended **30 September 2024** and the year to date results for the period 01 April 2024 to 30 September 2024, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations').
2. The Statement, which is the responsibility of the Company's management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

ZIM Laboratories Limited

Independent Auditor's Review Report on Standalone Unaudited Quarterly Financial Results and Year to Date Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

4. Based on our review conducted as above nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **Walker Chandiook & Co LLP**

Chartered Accountants

Firm Registration No:001076N/N500013

KHUSHROO Digitally signed by
B PANTHAKY KHUSHROO B PANTHAKY
Date: 2024.11.09 16:32:13
+05'30'

Khushroo B. Panthaky

Partner

Membership No:042423

UDIN:24042423BKCXMK1021

Place: Mumbai

Date: 09 November 2024



ZIM Laboratories Limited

Registered Office : Sadoday Gyan(Ground Floor),Opp.NADT,Nelson Square Nagpur - 440013, Maharashtra, India
CIN:L99999MH1984PLC032172, Website: www.zimlab.in

A. STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER & HALF YEAR ENDED 30 SEPTEMBER 2024

(Rs. in lakhs, unless otherwise stated)

Sr. No.	Particulars	Quarter ended			Half Year ended		Year ended
		30.09.2024	30.06.2024	30.09.2023	30.09.2024	30.09.2023	31.03.2024
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Income						
	a) Revenue from operations	8,972.13	8,200.41	8,525.95	17,172.54	15,226.66	36,547.32
	b) Other income	132.15	98.03	142.14	230.18	205.38	469.10
	Total income	9,104.28	8,298.44	8,668.09	17,402.72	15,432.04	37,016.42
2	Expenses						
	a) Cost of materials consumed	3,551.84	3,100.93	4,096.35	6,652.77	7,270.36	17,769.83
	b) Purchases of stock-in-trade	313.84	265.74	204.04	579.58	267.13	779.61
	c) Changes in inventories of finished goods, stock-in-trade and work-in-progress	287.20	314.37	(308.40)	601.57	(434.05)	(1,405.32)
	d) Employee benefits	1,443.76	1,348.05	1,224.49	2,791.81	2,436.89	5,081.03
	e) Finance costs	288.61	285.75	121.69	574.36	295.11	692.44
	f) Depreciation and amortisation	497.34	491.60	371.69	988.94	737.65	1,482.93
	g) Other expenses	2,536.53	2,383.58	2,413.26	4,920.11	4,336.24	10,311.93
	Total expenses	8,919.12	8,190.02	8,123.12	17,109.14	14,909.33	34,712.45
3	Profit before tax (1-2)	185.16	108.42	544.97	293.58	522.71	2,303.97
4	Tax expense						
	Current Tax	23.62	21.00	81.85	44.62	81.85	82.96
	Deferred Tax	39.97	11.52	45.33	51.49	37.37	545.46
	Total tax expense	63.59	32.52	127.18	96.11	119.22	628.42
5	Profit after tax (3-4)	121.57	75.90	417.79	197.47	403.49	1,675.55
6	Other comprehensive income - profit/(loss)						
	a) Items that will not be reclassified to profit or loss	(13.47)	(13.47)	(16.29)	(26.94)	(32.57)	(53.88)
	b) Tax (expense)/credit on the items that will not be reclassified to profit or loss	3.92	3.92	4.74	7.84	9.48	15.69
	Other comprehensive income (net of tax) - profit/(loss)	(9.55)	(9.55)	(11.55)	(19.10)	(23.09)	(38.19)
7	Total comprehensive income (5+6)	112.02	66.35	406.24	178.37	380.40	1,637.36
8	Paid-up equity share capital (face value of Rs. 10/- each)	4,872.58	4,872.58	4,872.58	4,872.58	4,872.58	4,872.58
9	Other equity (revaluation reserve : Rs. Nil)						18,322.84
10	Earnings per share (face value of Rs. 10/- each) (not annualised for quarters) (Rs.)						
	Basic	0.25	0.16	0.86	0.41	0.83	3.44
	Diluted	0.25	0.16	0.86	0.41	0.83	3.44



B. Standalone Balance Sheet

	As at 30.09.2024 Rs. in lakhs (Unaudited)	As at 31.03.2024 Rs. in lakhs (Audited)
ASSETS		
Non-current assets		
Property, Plant and Equipment	16,439.76	15,691.89
Capital work-in-progress	3,334.70	2,351.60
Intangible assets	299.68	357.43
Intangible assets under development	2,082.24	1,673.11
Financial Assets		
Investment in subsidiaries	972.15	817.81
Other Investments	5.15	5.15
Other financial assets	85.81	78.30
Non-current tax assets (net)	356.73	367.43
Other non-current assets	504.69	1,135.99
	24,080.91	22,478.71
Current assets		
Inventories	6,792.58	8,126.29
Financial Assets		
Trade receivables	7,266.91	10,009.25
Cash and cash equivalents	25.94	17.35
Bank balances other than cash and cash equivalents	64.95	57.99
Other financial assets	20.07	31.85
Other current assets	3,575.43	3,528.59
	17,745.88	21,771.32
TOTAL ASSETS	41,826.79	44,250.03
EQUITY AND LIABILITIES		
Equity		
Equity share capital	4,872.58	4,872.58
Other equity (Refer Note 5)	18,566.60	18,322.84
	23,439.18	23,195.42
Liabilities		
Non-current liabilities		
Financial Liabilities		
Borrowings	4,010.18	3,560.06
Lease Liabilities	352.55	294.95
Deferred tax liabilities (net)	1,053.74	1,010.09
	5,416.47	4,865.10
Current liabilities		
Financial Liabilities		
Borrowings	5,725.09	7,075.20
Lease Liabilities	333.79	247.18
Trade payables		
-total outstanding due of micro enterprises and small enterprises	68.49	6.31
-total outstanding due of creditors other than micro enterprises and small enterprises	4,749.21	6,260.15
Other financial liabilities	837.92	1,063.51
Other current liabilities	1,187.25	1,457.48
Provisions	57.26	79.68
Current Tax Liabilities (net)	12.13	-
	12,971.14	16,189.51
TOTAL LIABILITIES	18,387.61	21,054.61
TOTAL EQUITY AND LIABILITIES	41,826.79	44,250.03



C. Standalone Cash Flow Statement

	Half year ended 30.09.2024	Half year ended 30.09.2023
	Rs. in lakhs	Rs. in lakhs
	(Unaudited)	(Unaudited)
Cash flow from operating activities		
Profit before tax	293.58	522.71
Depreciation and amortisation expense	988.94	737.65
Government Incentive	(5.12)	(4.05)
Interest on Lease deposits	(3.61)	(1.69)
Loss on sale of property, plant and equipment (net)	0.71	1.11
Unrealized foreign exchange (Gain)	(78.40)	(69.13)
Provision for employee benefits	(26.94)	(32.57)
Dividend income on investments	(0.75)	(0.60)
Interest income	(1.90)	(2.82)
Employee compensation cost (ESOP costs)	19.03	-
Finance costs	574.36	295.11
Operating profit before working capital changes	1,759.90	1,445.72
Movement in working capital :		
(Decrease)in trade and other payables	(1,769.13)	(946.36)
(Increase)/decrease in inventories	1,333.71	(1,236.93)
Decrease in trade and other receivables	2,732.15	1,524.37
Net Cash generated from operations	4,056.63	786.80
Direct taxes paid (net of refunds)	(21.78)	624.56
Net cash from operating activities (A)	4,034.85	1,411.36
Cash flow from investing activities		
Purchases of property, plant and equipment and intangibles (Refer Note i)	(2,245.77)	(3,216.00)
Investment in subsidiary	(107.98)	-
Deposits placed with bank (having original maturity of more than three months)	(25.50)	(150.00)
Maturity of bank deposits (having original maturity of more than three months)	17.50	61.08
Interest received	0.19	1.48
Dividend received	0.75	0.60
Net cash (used in) investing activities (B)	(2,360.81)	(3,302.84)
Cash flow from financing activities		
Deemed equity contribution from shareholder (net)	-	2,140.24
Proceeds from long term borrowings	1,403.86	2,113.55
(Repayment) of long term borrowings	(690.05)	(650.66)
(Repayment) of short term borrowings	(1,545.32)	(1,334.94)
(Repayment) of lease obligations	(189.94)	(83.25)
Finance costs paid	(644.00)	(369.64)
Changes in unclaimed dividend bank balances	0.04	0.15
Dividends paid on equity shares (unclaimed)	(0.04)	(0.15)
Net cash generated from financing activities (C)	(1,665.45)	1,815.30
Net (decrease)/increase in cash and cash equivalents (A+B+C)	8.59	(76.18)
Opening cash and cash equivalents	17.35	110.98
Closing cash and cash equivalents	25.94	34.80
Components of cash and cash equivalents		
Cash on hand	16.26	20.32
Balances with banks in:		
- Current accounts	9.68	14.48
Total Cash and cash equivalents	25.94	34.80

Note (i) Includes capital work-in-progress, capital advance, payables for property, plant and equipment, intangibles assets and intangible assets under development.

Note (ii) The Statement of Cash flow has been prepared under the indirect method as set out in Indian Accounting Standard (Ind AS 7) Statement of Cash flows





Zeal & Innovation in **Medicine**

Annexure A

Details under amended Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read along with SEBI Circular No. SEBI/HO/CFD/CFDPoD-1/P/CIR/2023/123 dated 13th July, 2023

Sr. No.	Particulars	Details
1.	Reason for change viz. appointment, re-appointment, resignation, removal, death or otherwise	Dr. Chandrashekhar Mainde designated as Technical Director categorized as Senior Management Personnel of the Company.
2.	Date of appointment/re-appointment/cessation	Dr. Chandrashekhar Mainde currently serving as Technical Director of the Company, has been categorized as Senior Management Personnel of the Company effective 09 th November, 2024
3.	Brief profile (in case of appointment)	Dr. Chandrashekhar Mainde, M. Pharm, Ph.D. in Pharmaceutical Technology, is the Technical Director at ZIM Laboratories Limited (ZIM) and a seasoned pharmaceutical expert with over 25 years in the industry. His expertise spans major regulatory audits, including those by the US FDA, MHRA, ANVISA, TGA, and EMA. He has successfully managed the filing of 10 ANDAs in the USA and 50 EU dossiers. As a principal investigator, he has filed several Indian and international patents. Dr. Mainde's strategic focus on innovative drug delivery and value-added, differentiated generics has strengthened ZIM's reputation in both regulated and emerging markets.
4.	Disclosure of relationships between directors (in case of appointment of a director)	Not Applicable

ZIM LABORATORIES LIMITED

www.zimlab.in | info@zimlab.in | CIN : L99999MH1984PLC032172



Zeal & Innovation in **M**edicine

Details under amended Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read along with SEBI Circular No. SEBI/HO/CFD/CFDPoD-1/P/CIR/2023/123 dated 13th July, 2023

Sr. No.	Particulars	Details
1.	Reason for change viz. appointment, re-appointment, resignation, removal, death or otherwise	Dr. Uttam Kedar designated as Assistant Vice President – R&D categorized as Senior Management Personnel of the Company.
2.	Date of appointment/re-appointment/cessation	Dr. Uttam Kedar currently serving as Assistant Vice President – R&D of the Company, has been categorized as Senior Management Personnel of the Company effective 09 th November, 2024
3.	Brief profile (in case of appointment)	Dr. Uttam Kedar, Assistant Vice President - R&D at ZIM Laboratories Limited, holds an M.Pharm and Ph.D. in Pharmaceutical Sciences. With over 18 years of experience in product development, he specializes in oral solid dosage forms and leads research on advanced drug delivery technologies aimed at improving bioavailability, patient compliance, and therapeutic efficacy.
4.	Disclosure of relationships between directors (in case of appointment of a director)	Not Applicable

ZIM LABORATORIES LIMITED

www.zimlab.in | info@zimlab.in | CIN : L99999MH1984PLC032172